Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene
5 Healthcare Innovators I'm Still Buying
by Kevin Cook
When you think long-term about the megatrends in healthcare, it makes picking winners easier
Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.
Alexion (ALXN) Tops Q1 Earnings, Sales; Shares Up
by Zacks Equity Research
Alexion surpassed earnings and sales expectations in the first quarter of 2017.
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
by Arpita Dutt
Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Alexion (ALXN) Files for Soliris' Label Expansion in Japan
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.
Alexion's sBLA for Soliris Receives FDA Acknowledgement
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris
Is This the Right Time to Invest in Biotech Stocks?
by Arpita Dutt
The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?
Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More
by Zacks Equity Research
With the curtains almost down on the Q4 earnings season, we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years.
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
by Zacks Equity Research
The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
by Arpita Dutt
While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.
Forget Alexion, Buy these 4 Biotech Stocks Instead
by Arpita Dutt
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
by Zacks Equity Research
Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.
Alexion (ALXN) Misses on Q4 Earnings and Revenues
by Zacks Equity Research
Alexion missed on earnings expectations in the fourth quarter of 2016.
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
by Arpita Dutt
Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
by Zacks Equity Research
Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
by Zacks Equity Research
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Company News for January 06, 2017
by Zacks Equity Research
Companies In The News are: ALXN,CEB,IT,SHLD,SWK,HALO